BACKGROUND:
• Bipolar II disorder is distinguished from Bipolar I due to patients spending more time in the depressed phase than in the hypomanic phase. • Current recommendations for Bipolar II disorder include a mood stabilizer as a monotherapy; however current practice involves the potential addition of an antidepressant. • The use of selective serotonin reuptake inhibitors (SSRIs) in a Bipolar I patients is contraindicated due to increased risk of mania. SSRI monotherapy has yet to be studied in Bipolar II patients to determine if increased risk of hypomania exists.
OBJECTIVE
• To determine whether the use of SSRI monotherapy in Bipolar II patients increases the frequency of switching to hypomanic states; to assess the safety and treatment response rates for SSRI monotherapy, a mood stabilizer monotherapy, and a combination of both.
METHODS
• Design: Randomized, double-blind, parallel, multicenter, controlled experimental study; Duration: 16 weeks • Inclusion criteria: 18-65 years of age who met DSM-IV criteria for bipolar II disorder, were in a current major depressive episode, had a score of ≥ 22 (moderate or greater severity) on the Inventory of Depressive Symptomatology-Clinician Rated (IDS-C) scale, a score of ≤ 8 on the Young Mania Rating Scale (YMRS), a score of ≥ 3 on the depression severity subscale of the Clinical Global Impressions Scale for Bipolar Disorder (CGI-BP) and a mania severity subscale score of 1 (not ill) on the CGI-BP • Exclusion criteria: Mixed symptoms or psychosis, suicidality, a substance use disorder within the previous 3 months, a past history of nonresponse to lithium or sertraline for depression with ≥ 6 weeks of treatment at an adequate dosage • Primary outcome measure: Frequency of switching to hypomanic state as defined by the Young Mania Rating Scale (YMRS) and the Clinical Global Impression for Bipolar Disorder (CGI-BP) scale, or mania as defined by the DSM-IV and confirmed by the Structured Clinical Interview for DSM-IV (SCID). • Secondary outcome measures: Treatment response as defined by the Inventory of Depressive Symptomatology (IDS-C) scale, or the CGI-BP scale, incidence of treatmentemergent side effects, and dropout rate • 142 patients were randomized to receive either:
o Lithium at a minimum goal of 900 mg/day, titrated to therapeutic response OR o Sertraline at a minimum goal of 100 mg/day, titrated to response OR o Lithium + sertraline at their respective minimum doses, titrated to response • Power of 80% with an alpha level of 0.05 to detect large differences in switch rates based on a sample size of 142 with an expected 50% dropout rate • Data handling method was intent-to-treat
RESULTS
• 62 patients completed the study: 22 in the lithium group, 26 in the sertraline group, and 14 in the combination group
• Primary outcome measure: An estimated 14% of participants experienced a switch to a hypomanic state; there was an estimated switch rate of 19.4% in the lithium group, 19.9% in the sertraline group, and 13.4% in the combination group after accounting for early study discontinuation. The difference was not statistically significant (p=0.784). 75% of switches occurred in the first 5 weeks of treatment • Secondary outcome measures: 62.7% of participants met treatment response criteria during the study period. The monotherapy groups exhibited a greater incidence of response than the combination therapy group, however this was not significant (p=0.093). Patients in the combination therapy group had a significantly greater dropout rate of 34 (compared to 27 and 19) (p=0.031). The difference in treatment-emergent side effects was not statistically significant. • Author's conclusion: Lithium monotherapy, sertraline monotherapy, and lithium/sertraline combination therapy is associated with equivalent switch rates. Also, monotherapy is associated with less treatment discontinuation than combination therapy. • Although the study showed that switch rates were not increased with SSRI monotherapy, the study had many limitations that restrict the validity of the results. • Despite the limitations, it appears safe to consider SSRI monotherapy as a later-line option in patients who can not tolerate a mood stabilizer or combination therapy. • Future research would be beneficial with a larger sample size, longer duration, and therapeutic lithium levels.
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